Bivalirudin versus heparin in ACS PCI: a mortality and bleeding signal

Design

Meta-analysis of 11 randomised trials and 17 cohort studies

Population

584,249 adults with acute coronary syndrome undergoing PCI

Primary outcome

Mortality, major bleeding and ischaemic events

Effect

30-day all-cause mortality RR 0.85 (95% CI 0.76-0.95); major bleeding RR 0.59 (0.49-0.72)

This meta-analysis pooled 11 randomised trials and 17 cohort studies, 584,249 patients in all, comparing bivalirudin with heparin for anticoagulation during percutaneous coronary intervention in acute coronary syndrome.

Bivalirudin was associated with lower in-hospital all-cause mortality (relative risk 0.86) and major bleeding (relative risk 0.74). At 30 days the pattern held: all-cause mortality relative risk 0.85, cardiovascular mortality 0.81, major bleeding 0.59 and net adverse clinical events 0.79. There was no difference in major adverse cardiovascular events, myocardial infarction, stent thrombosis or stroke, so the benefit tracks bleeding and its downstream mortality rather than ischaemic protection.

The weight of evidence sits in observational cohorts, where sicker or higher-bleeding-risk patients may have been steered towards one drug. Treat this as support for considering bivalirudin in selected ACS PCI patients, especially where bleeding risk is high, not as proof that switching anticoagulant lowers death.

• Pooled 11 randomised trials and 17 cohort studies, 584,249 patients undergoing PCI for acute coronary syndrome.
• 30-day all-cause mortality was lower with bivalirudin (relative risk 0.85) as was cardiovascular mortality (0.81).
• Major bleeding was substantially lower with bivalirudin (30-day relative risk 0.59).
• There was no difference in ischaemic events: MACE, myocardial infarction, stent thrombosis or stroke.
• Weigh bivalirudin where bleeding risk is high, alongside radial access and careful heparin dosing.

Why it matters

The mortality difference appears to run through bleeding, not ischaemia, so bleeding-avoidance strategy is the lever, not the drug alone.

Don't overread it

Most of the data came from observational cohorts, which cannot exclude confounding by indication; this is not proof that switching anticoagulant reduces death.

The statistics, in plain English

A relative risk of 0.59 for major bleeding means about a 41% lower rate, and the confidence interval (0.49 to 0.72) stays well below 1.0, so the bleeding reduction is unlikely to be chance. But pooling randomised and observational studies mixes designs, and the very tight mortality interval (0.84 to 0.88) partly reflects huge cohort numbers rather than trial quality.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.